GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Shiller PE Ratio

Sorrento Therapeutics (LTS:0L85) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sorrento Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Sorrento Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Shiller PE Ratio Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sorrento Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Sorrento Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sorrento Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Shiller PE Ratio falls into.



Sorrento Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sorrento Therapeutics's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Sorrento Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.17/128.7287*128.7287
=-0.170

Current CPI (Jun. 2023) = 128.7287.

Sorrento Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.240 98.790 -0.313
201312 -0.660 98.326 -0.864
201403 -0.440 99.695 -0.568
201406 -0.330 100.560 -0.422
201409 -0.270 100.428 -0.346
201412 -0.280 99.070 -0.364
201503 -0.290 99.621 -0.375
201506 -0.300 100.684 -0.384
201509 -0.030 100.392 -0.038
201512 -0.630 99.792 -0.813
201603 -0.410 100.470 -0.525
201606 -0.930 101.688 -1.177
201609 0.240 101.861 0.303
201612 -0.300 101.863 -0.379
201703 -0.450 102.862 -0.563
201706 -0.200 103.349 -0.249
201709 -0.030 104.136 -0.037
201712 0.720 104.011 0.891
201803 -0.380 105.290 -0.465
201806 -0.730 106.317 -0.884
201809 -0.400 106.507 -0.483
201812 -0.400 105.998 -0.486
201903 -0.880 107.251 -1.056
201906 -0.470 108.070 -0.560
201909 -0.500 108.329 -0.594
201912 -0.370 108.420 -0.439
202003 -0.360 108.902 -0.426
202006 -0.360 108.767 -0.426
202009 -0.330 109.815 -0.387
202012 -0.250 109.897 -0.293
202103 0.010 111.754 0.012
202106 -0.570 114.631 -0.640
202109 -0.400 115.734 -0.445
202112 -0.470 117.630 -0.514
202203 -0.120 121.301 -0.127
202206 -0.540 125.017 -0.556
202209 -0.200 125.227 -0.206
202212 -0.490 125.222 -0.504
202303 -0.260 127.348 -0.263
202306 -0.170 128.729 -0.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sorrento Therapeutics  (LTS:0L85) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sorrento Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sorrento Therapeutics (LTS:0L85) Business Description

Traded in Other Exchanges
Address
4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines